HALO (Halozyme Therapeutics) Float Percentage Of Total Shares Outstanding: 77.31% (As of Jul. 03, 2026)


HALO Halozyme Therapeutics Inc HALO
92 GF Score
Price $79.47
GF Value $90.71
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Float Percentage Of Total Shares Outstanding?

Halozyme Therapeutics HALO +3.17% 92 Float Percentage Of Total Shares Outstanding is 77.31% as of Jul. 03, 2026. GuruFocus rates HALO with a GF Score™ of 92/100 and a GF Value™ of $90.71 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Halozyme Therapeutics's float shares is 91.70 Mil. Halozyme Therapeutics's total shares outstanding is 118.61 Mil. Halozyme Therapeutics's float percentage of total shares outstanding is 77.31%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Halozyme Therapeutics's Insider Ownership is 9.81%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Halozyme Therapeutics's Institutional Ownership is 111.53%.

HALO
92GF Score
Halozyme Therapeutics Inc HALO
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Halozyme Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Halozyme Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=91.70/118.61
=77.31%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 77.31% mean?
Halozyme Therapeutics (HALO) has a Float Percentage Of Total Shares Outstanding of 77.31% as of Jul. 03, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Halozyme Therapeutics' current Float Percentage Of Total Shares Outstanding is 77.31%. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Float Percentage Of Total Shares Outstanding compare to KYMR and IBRX?
Halozyme Therapeutics' Float Percentage Of Total Shares Outstanding of 77.31% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Float Percentage Of Total Shares Outstanding is 77.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.71, compared to a current price of $79.47 — trading 12.4% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 77.31%. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Float Percentage Of Total Shares Outstanding is 77.31% as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued. The current stock price of $79.47 is trading 12.4% below its estimated GF Value™ of $90.71. GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.

Key valuation signals for HALO:

  • Float Percentage Of Total Shares Outstanding: 77.31%
  • GF Value™: $90.71 vs. price of $79.47 (12.4% below fair value)
  • GF Score™: 92/100 with 3 warning signs

No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score

Get the complete analysis for HALO

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$79.47
Price
$90.71
GF Value